Iovance Biotherapeutics, Inc. (IOVA)

NASDAQ: IOVA · IEX Real-Time Price · USD

7.73

-0.33 (-4.09%)

At close: Jul 2, 2024, 4:00 PM

7.74

+0.01 (0.14%)

After-hours: Jul 2, 2024, 7:54 PM EDT

Iovance Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2007
Revenue	1.19	0	0	0	0	Upgrade
Cost of Revenue	10.76	0	0	0	0	Upgrade
Gross Profit	-9.57	0	0	0	0	Upgrade
Selling, General & Admin	106.92	104.1	83.66	60.21	40.85	Upgrade
Research & Development	344.08	294.78	259.04	201.73	166.02	Upgrade
Operating Expenses	450.99	398.88	342.7	261.94	206.87	Upgrade
Operating Income	-460.56	-398.88	-342.7	-261.94	-206.87	Upgrade
Other Expense / Income	-13.04	-2.99	-0.45	-2.36	-9.32	Upgrade
Pretax Income	-447.52	-395.89	-342.25	-259.58	-197.56	Upgrade
Income Tax	-3.48	0	0	0	0	Upgrade
Net Income	-444.04	-395.89	-342.25	-259.58	-197.56	Upgrade
Shares Outstanding (Basic)	235	159	153	138	124	Upgrade
Shares Outstanding (Diluted)	235	159	153	138	124	Upgrade
Shares Change	47.64%	3.82%	10.92%	11.23%	27.82%	Upgrade
EPS (Basic)	-1.89	-2.49	-2.23	-1.88	-1.59	Upgrade
EPS (Diluted)	-1.89	-2.49	-2.23	-1.88	-1.59	Upgrade
Free Cash Flow	-384.11	-313.18	-265.52	-251.93	-165.81	Upgrade
Free Cash Flow Per Share	-1.63	-1.97	-1.73	-1.82	-1.33	Upgrade
Gross Margin	-804.54%	-	-	-	-	Upgrade
Operating Margin	-38734.99%	-	-	-	-	Upgrade
Profit Margin	-37345.42%	-	-	-	-	Upgrade
Free Cash Flow Margin	-32305.30%	-	-	-	-	Upgrade
EBITDA	-414.39	-374.76	-328.27	-250.87	-189.43	Upgrade
EBITDA Margin	-34851.89%	-	-	-	-	Upgrade
Depreciation & Amortization	33.13	21.14	13.98	8.71	8.12	Upgrade
EBIT	-447.52	-395.89	-342.25	-259.58	-197.56	Upgrade
EBIT Margin	-37638.02%	-	-	-	-	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).